Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vical deal

VICL said the total value of the deal, excluding royalties,

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE